Project Details
Description
A phase 3, open-label, randomized, multicenter, 12 months, efficacy and safety study of weekly MOD-4023 compared to daily Genotropin therapy in pre-pubertal children with growth hormone deficiency
| Status | Active |
|---|---|
| Effective start/end date | 10/10/16 → 6/30/24 |
Funding
- OPKO BIOLOGICS, LTD
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.